London's Shire said it was seeking to buy U.S. firm Baxalta in a $30 billion deal to create a global specialist in medicines treating rare diseases.» Read More
CVS spokesman Michael DeAngelis said the Rhode Island-based company had not been served with the lawsuit, so he couldn't comment.
Former Allergan CEO David Pyott tells a Senate hearing the SEC should investigate the Pershing Square-Valeant alliance.
GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.
The CEO of German drugmaker Bayer has quashed any talk of acquiring its competitor Syngenta, which is being pursued by U.S. firm Monsanto.
Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.
Barbara Ryan, Clermont Partners, breaks down Pfizer and Merck's quarterly results and shares her outlook on the pharmaceutical sector.
Teva will acquire Allergan's generics unit for $40.5 billion. CNBC's Meg Tirrell takes a look at other potential M&A action in the space.
Chart analyst John Kosar shows how investors can profit from the pullback in oil prices.
Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.
One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.
CNBC's Meg Tirrell reports on the FDA approving Regeneron's cholesterol drug Praluent.
Shares of Regeneron were down about 3 percent after the FDA approved Regeneron's cholesterol-lowering drug Praluent on Friday.
CNBC's Meg Tirrell reports on a Glaxo Malaria vaccine for use in Sub-Saharan Africa as it seeks the final steps to approval.
CNBC's Meg Tirrell looks ahead at pharma earnings to come. FMHR traders weigh in on the health care space.
CNBC's Meg Tirrell reports on Biogen's sales growth as the company misses sales estimates.
Biogen shares sank after it lowered its 2015 forecast on slower-than-anticipated growth of its multiple sclerosis blockbuster Tecfidera.
Jim Cramer explains why he is watching shares of Biogen after the company lowered its guidance
Hans Bishop, Juno Therapeutics CEO, discusses advances made in immunotherapy to treat cancers and other types of tumors by using the body's immune system to defend itself.
Yossi Pollak, chief executive officer at Sight Diagnostics, explains how computer algorithms make blood testing more efficient.
The world's first malaria vaccine got a green light on Friday from European drugs regulators.
Get the best of CNBC in your inbox